Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma.
Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma.
复制标题
DOI：
10.1309/ajcp59uorcyzevqo
复制
发表时间：
2012-01
影响因子：
3.5
通讯作者：
Lorsbach RB
中科院分区：
文献类型：
--
作者：
Alapat D;Coviello-Malle J;Owens R;Qu P;Barlogie B;Shaughnessy JD;Lorsbach RB
The membrane glycoprotein MRC OX-2 (CD200) is expressed in several lymphoid malignancies. However, the diagnostic utility and potential prognostic importance of CD200 expression have not been rigorously examined. We show that CD200 is uniformly expressed in chronic lymphocytic leukemia (CLL) and absent in mantle cell lymphoma (MCL). Importantly, expression of CD200 is retained even in those CLLs with immunophenotypic aberrancies, making CD200 a particularly useful marker for discrimination between these cases and MCL. CD200 is expressed in nearly all precursor B lymphoblastic leukemias, with aberrant over- or underexpression when compared to normal B-cell progenitors in 55% of cases. Over 70% of plasma cell myelomas (PCMs) expressed CD200, and loss of CD200 expression in PCM may be associated with more clinically aggressive disease. In summary, CD200 is expressed in several hematolymphoid neoplasms. Analysis of its expression has several diagnostic, and potentially prognostic, applications in the flow cytometric evaluation of lymphoid malignancies.
